Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Cancer Prev Res (Phila). 2009 Mar 31;2(4):370–376. doi: 10.1158/1940-6207.CAPR-08-0209

Fig. 2.

Fig. 2

Effect of myoinositol on the levels of P-Akt and P-ERK in bronchial lesions analyzed with immunohistochemistry by per-site and subject analyses. Total baseline bronchial sites (103) include 31 dysplastic sites, 67 hyper/metaplastic sites, and 5 normal sites. Top, the staining index was expressed as mean ± SE; bottom, changes in staining indices for P-Akt and P-ERK from all pretreatment and posttreatment bronchial epithelial sites.

HHS Vulnerability Disclosure